FDA Approves New NET Diagnostic Imaging Radiopharmaceutical

The U.S. Food and Drug Administration (FDA) has approved Detectnet™, copper Cu 64 dotatate injection. This is a new diagnostic radiopharmaceutical for use with positron emission tomography (PET) for the detection, localization, and monitoring of somatostatin receptor positive neuroendocrine tumors. Read more about copper Cu 64, https://www.curiumpharma.com/2020/09/08/radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-u-s/.

Detectnet logo_2

Print Friendly, PDF & Email